Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Synthesis and Anti-HIV-1 Activity of a Novel Series of Aminoimidazole Analogs.

Ganguly S, Murugesan S, Prasanthi N, Alptürk O, Herman B, Sluis-Cremer N.

Lett Drug Des Discov. 2010 Jun 1;7(5):318-323.

2.

Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.

Buckheit RW Jr, White EL, Fliakas-Boltz V, Russell J, Stup TL, Kinjerski TL, Osterling MC, Weigand A, Bader JP.

Antimicrob Agents Chemother. 1999 Aug;43(8):1827-34.

4.

Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.

Lai MT, Munshi V, Touch S, Tynebor RM, Tucker TJ, McKenna PM, Williams TM, DiStefano DJ, Hazuda DJ, Miller MD.

Antimicrob Agents Chemother. 2009 Jun;53(6):2424-31. doi: 10.1128/AAC.01559-08. Epub 2009 Mar 16.

5.

TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.

Azijn H, Tirry I, Vingerhoets J, de Béthune MP, Kraus G, Boven K, Jochmans D, Van Craenenbroeck E, Picchio G, Rimsky LT.

Antimicrob Agents Chemother. 2010 Feb;54(2):718-27. doi: 10.1128/AAC.00986-09. Epub 2009 Nov 23.

6.

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, Janssen P, De Corte B, Vingerhoets J, Pauwels R, de Béthune MP.

Antimicrob Agents Chemother. 2004 Dec;48(12):4680-6.

7.

In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

Wildum S, Paulsen D, Thede K, Ruebsamen-Schaeff H, Zimmermann H.

Antimicrob Agents Chemother. 2013 Nov;57(11):5320-9. doi: 10.1128/AAC.01377-13. Epub 2013 Aug 19.

8.

Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates.

Buckheit RW Jr, Snow MJ, Fliakas-Boltz V, Kinjerski TL, Russell JD, Pallansch LA, Brouwer WG, Yang SS.

Antimicrob Agents Chemother. 1997 Apr;41(4):831-7.

10.

Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide.

Buckheit RW Jr, Kinjerski TL, Fliakas-Boltz V, Russell JD, Stup TL, Pallansch LA, Brouwer WG, Dao DC, Harrison WA, Schultz RJ, et al.

Antimicrob Agents Chemother. 1995 Dec;39(12):2718-27.

11.

Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.

Varghese V, Shahriar R, Rhee SY, Liu T, Simen BB, Egholm M, Hanczaruk B, Blake LA, Gharizadeh B, Babrzadeh F, Bachmann MH, Fessel WJ, Shafer RW.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):309-15. doi: 10.1097/QAI.0b013e3181bca669.

12.

Calanolides, the naturally occurring anti-HIV agents.

Xu ZQ, Flavin MT, Jenta TR.

Curr Opin Drug Discov Devel. 2000 Mar;3(2):155-66.

PMID:
19649847
13.

Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.

Taylor DL, Ahmed PS, Chambers P, Tyms AS, Bedard J, Duchaine J, Falardeau G, Lavallée JF, Brown W, Rando RF, Bowlin T.

Antivir Chem Chemother. 1999 Mar;10(2):79-86.

PMID:
10335402
14.
15.

TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments.

Vingerhoets J, Azijn H, Fransen E, De Baere I, Smeulders L, Jochmans D, Andries K, Pauwels R, de Béthune MP.

J Virol. 2005 Oct;79(20):12773-82.

16.

Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.

Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R, Rizzo C.

J Virol. 2001 Jun;75(11):4999-5008.

17.

Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1.

Corbau R, Mori J, Phillips C, Fishburn L, Martin A, Mowbray C, Panton W, Smith-Burchnell C, Thornberry A, Ringrose H, Knöchel T, Irving S, Westby M, Wood A, Perros M.

Antimicrob Agents Chemother. 2010 Oct;54(10):4451-63. doi: 10.1128/AAC.01455-09. Epub 2010 Jul 26.

18.

Identification and characterization of a novel HIV-1 nucleotide-competing reverse transcriptase inhibitor series.

Rajotte D, Tremblay S, Pelletier A, Salois P, Bourgon L, Coulombe R, Mason S, Lamorte L, Sturino CF, Bethell R.

Antimicrob Agents Chemother. 2013 Jun;57(6):2712-8. doi: 10.1128/AAC.00113-13. Epub 2013 Apr 1.

19.

Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants.

Dykes C, Fox K, Lloyd A, Chiulli M, Morse E, Demeter LM.

Virology. 2001 Jul 5;285(2):193-203.

20.

Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.

Ceccherini-Silberstein F, Svicher V, Sing T, Artese A, Santoro MM, Forbici F, Bertoli A, Alcaro S, Palamara G, d'Arminio Monforte A, Balzarini J, Antinori A, Lengauer T, Perno CF.

J Virol. 2007 Oct;81(20):11507-19. Epub 2007 Aug 8.

Items per page

Supplemental Content

Write to the Help Desk